Vidac Pharma Holding Plc (ETR:T9G)

Market Cap	29.74M
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	51.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	10,550
Open	0.5500
Previous Close	0.5520
Day's Range	0.5220 - 0.5880
52-Week Range	0.4500 - 0.9600
Beta	n/a
RSI	49.01
Earnings Date	Jun 30, 2026

About Vidac Pharma Holding

Vidac Pharma Holding Plc, an investment holding company, engages in the discovery and development of medicines for oncologic and dermatologic diseases. The company is developing VDA-1102 ointment, an anti-neoplastic agent that is in Phase 2 clinical trials for triggering apoptosis in cancer cells with minimal effects on surrounding normal cells. It is also developing VDA-1102 IV, an anti-neoplastic agent; and VDA-1275, a potent small molecule new chemical entity that are in preclinical stage for use in the treatment of solid tumors. The company...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2021
• Country: United Kingdom
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: T9G